Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2024British Journal of HaematologyOpen Access

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJaimal KothariTEToby A. EyreARAli Rismani

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kothari et al. (2024) studied this question.

synapsesocial.com/papers/68e5bb2db6db643587553552https://doi.org/10.1111/bjh.19706
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy2015 · 56 citations
  2. 2How I treat Waldenström macroglobulinemia2019 · 104 citations
  3. 3Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study2015 · 131 citations
  4. 4Treatment of relapsed and refractory Waldenstrom Macroglobulinemia2022 · 2 citations
  5. 5Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia2018 · 348 citations